基于网络药理学和分子对接探讨扶正抑瘤汤治疗肺腺癌的作用机制
The Mechanism of Fu Zheng Yi Liu Tang for Treatment of Lung Adenocarcinoma Based on Network Pharmacology and Molecular Docking Technology
DOI: 10.12677/ACM.2022.12111407, PDF,    国家自然科学基金支持
作者: 吴 雨, 陈佳玥, 王国瑞, 卢丽莎, 朱雄雄, 张 舟, 田一虹, 吴建军*：甘肃中医药大学公共卫生学院，甘肃 兰州；甘肃中医药大学中医预防医学研究所，甘肃 兰州
关键词: 肺腺癌；扶正抑瘤汤；网络药理学；中药；分子对接；Lung Adenocarcinoma； Fu Zheng Yi Liu Tang； Network Pharmacology； Traditional Chinese Medicine； Molecular Docking
摘要: 目的：利用网络药理学方法及分子对接从整体观念探讨扶正抑瘤汤治疗肺腺癌的作用机制。方法：通过TCMSP数据库检索筛选扶正抑瘤汤中的四味中药的有效成分并其靶点，利用GeneCards数据库检索肺腺癌的疾病基因，绘制Venny图获取交集基因，利用Cytoscape 3.8.0软件获取重要蛋白，构建成分–靶点–疾病–通路网络。利用R语言进行GO富集分析和KEGG富集分析。结果：扶正抑瘤汤四味中药共筛选出17个有效成分，涉及基因194个。涉及的生物学过程主要包括对脂多糖的反应等条目；涉及的分子功能主要包括受体配体的活性等条目；涉及细胞组成主要集中在膜筏板等条目。其作用机制与血脂和动脉粥样硬化等通路有关。结论：本研究初步揭示了扶正抑瘤汤多靶点整体调节肺腺癌的作用特点，为进一步开展扶正抑瘤汤治疗肺腺癌作用机制的研究提供了新的思路和研究方法。
Abstract: Objective: To explore the mechanism of the treatment of lung adenocarcinoma by using network pharmacological methods and molecular docking. Methods: The active components of the four Chi-nese herbs were selected and targeted by TCMSP database, the disease genes of lung adenocarci-noma were retrieved by GeneCards database, Venny map was drawn, and Cytoscape 3.8.0 software was used, and the component-target-disease-pathway network was constructed. The GO enrichment analysis and the KEGG enrichment analysis were performed using the R language. Results: A total of 17 active ingredients involved 194 genes. The biological processes involved include the reaction to LPS, the molecular functions including the activity of the receptor ligand, and the cell composition focusing on membrane rafts. The mechanism of action is related to pathways such as blood lipids and atherosclerosis. Conclusion: This study preliminarily revealed the role of multiple target points of zheng tumor suppression soup in regulating lung adenocarcinoma, and provided new ideas and research methods for the treatment mechanism of lung adenocarcinoma.
文章引用：吴雨, 陈佳玥, 王国瑞, 卢丽莎, 朱雄雄, 张舟, 田一虹, 吴建军. 基于网络药理学和分子对接探讨扶正抑瘤汤治疗肺腺癌的作用机制[J]. 临床医学进展, 2022, 12(11): 9756-9768. https://doi.org/10.12677/ACM.2022.12111407

参考文献

[1] Denisenko, T.V., Budkevich, I.N. and Zhivotovsky, B. (2018) Cell Death-Based Treatment of Lung Adenocarcinoma. Cell Death & Disease, 9, Article No. 117. [Google Scholar] [CrossRef] [PubMed]
[2] 史浩明, 吴庆琛. IB期肺腺癌术后复发转移因素研究[J]. 医学信息, 2021, 34(4): 92-95.
[3] 吴建军, 许瑞, 张艳霞, 等. 扶正抑瘤汤对胶质瘤裸鼠肿瘤生长抑制的影响[J]. 中成药, 2020, 42(3): 620-625.
[4] 封士兰, 何禄仁, 甘雨良, 等. 扶正抑瘤颗粒的指纹图谱研究[J]. 浙江师范大学学报(自然科学版), 2006, 29(4): 420-424.
[5] 舒心, 郭擎, 高彦祥. 槲皮素及其递送体系的研究进展[J]. 食品科学, 2022, 43(7): 202-212.
[6] Kim, S., Yoo, E., Woo, J., et al. (2019) Anti-tumor and Apoptotic Effects of Quercetin on Human Melanoma Cells Involving JNK/P38 MAPK Signaling Activation. European Journal of Pharmacology, 860, Article ID: 172568. [Google Scholar] [CrossRef] [PubMed]
[7] Yang, J.H., Hsia, T.C., Kuo, H.M., et al. (2006) Inhibition of Lung Cancer Cell Growth by Quercetin Glucuronides via G2/M Arrest and Induction of Apoptosis. Drug Metabolism, 34, 296-304. [Google Scholar] [CrossRef] [PubMed]
[8] 顾超, 徐水凌, 唐文稳, 等. 槲皮素诱导HeLa细胞凋亡及caspase-3、caspase-8活化对凋亡影响的研究[J]. 中国药学杂志, 2011, 46(8): 595-599.
[9] 李林, 王迪进, 万轲, 等. 槲皮素对人肺腺癌NCI-H1395细胞凋亡的影响[J]. 中国药房, 2015, 26(34): 4786-4788.
[10] 叶艺旺, 乌达, 刘继先, 等. FasL和Caspase-8蛋白表达及Caspase-8基因甲基化在非小细胞肺癌中的应用价值研究[J]. 中国药业, 2017, 26(12): 1-7.
[11] 欧颖璨. 槲皮素诱导肿瘤细胞程序性坏死的机制研究[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2020.
[12] Lu, W.L., et al. (2020) Cytotoxicity of Naringenin Induces Bax-Mediated Mitochondrial Apoptosis in Human Lung Adenocarcinoma A549 Cells. Environmental Toxicology, 35, 1386-1394. [Google Scholar] [CrossRef] [PubMed]
[13] 王旭红, 刘改霞, 李耀辉, 等. 基于网络药理学探寻β-谷甾醇作用机制研究[J]. 世界中医药, 2022, 17(2): 172-176.
[14] 李国强, 李韵仪, 谭卓杰. β-谷甾醇的波谱结构解析[J]. 广东化工, 2018, 45(10): 128+116.
[15] Gao, S.P., Kiliti, A.J., Zhang, K., et al. (2021) AKT1 E17K Inhibits Cancer Cell Mi-gration by Abrogating β-Catenin Signaling. Molecular Cancer Research, 19, 573-584. [Google Scholar] [CrossRef] 
[16] Islas-Vazquez, L., Aguilar-Cazares, D., Galicia-Velasco, M., et al. (2020) IL-6, NLR, and SII Markers and Their Relation with Alterations in CD8+ T-Lymphocyte Subpopula-tions in Patients Treated for Lung Adenocarcinoma. Biology, 9, Article No. 376. [Google Scholar] [CrossRef] [PubMed]
[17] Hsu, M.C., Pan, M.R. and Hung, W.C. (2019) Two Birds, One Stone: Double Hits on Tumor Growth and Lymphangiogenesis by Targeting Vascular Endothelial Growth Factor Receptor 3. Cells, 8, E270. [Google Scholar] [CrossRef] [PubMed]
[18] 李璟波, 张文, 夏晖, 等. 肺腺癌组织血管内皮生长因子受体3(VEGFR3)高表达与患者预后不良正相关[J]. 细胞与分子免疫学杂志, 2019, 35(11): 1023-1029.
[19] Kitaura, H., Shimshi, M., Vchikoshi, Y., et al. (2000) Reciprocal Regulation via Protein-Protein Interaction between c-myc and p21cip/waf1/sdi1 in DNA Replication and Transcription. Journal of Biological Chemistry, 275, 10477- 10483. [Google Scholar] [CrossRef] [PubMed]
[20] 迟万好, 曹明富, 朱睦元. 细胞凋亡的基因调控研究进展[J]. 杭州师范学院学报(自然科学版), 2001(5): 45-49.
[21] Roskoski, R.J. (2014) The ErbB/HER Family of Pro-tein-Tyrosine Kinases and Cancer. Pharmacological Research, 79, 34-74. [Google Scholar] [CrossRef] [PubMed]
[22] 马阳, 吴娟, 纪晓坤, 等. 沉默表皮生长因子受体的表达对肺腺癌A549细胞自噬的影响[J]. 癌变•畸变•突变, 2019, 31(5): 347-351+358.
[23] 伍锦凤, 何杰. 非小细胞肺癌中EGFR、ALK、ROS1基因突变和PD-L1表达及临床意义[J]. 临床与实验病理学杂志, 2022(9): 1133-1136.
[24] 庞诗晓, 安德琪. 表皮生长因子受体基因突变晚期非小细胞肺癌靶向药物治疗的临床效果[J]. 临床合理用药杂志, 2022, 15(23): 9-12.

为你推荐